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Abstract: The rapid escalation in the global prevalence diabetes, with more than 30% being afflicted with diabetic reti-
nopathy (DR), means it is likely that associated vision-threatening conditions will also rise substantially. This means that 
new therapeutic approaches need to be found that go beyond the current standards of diabetic care, and which are effective 
in the early stages of the disease. In recent decades several new pharmacological agents have been investigated for their 
effectiveness in preventing the appearance and progression of DR or in reversing DR; some with limited success while 
others appear promising. This up-to-date critical review of non-traditional systemic treatments for DR is based on the pub-
lished evidence in MEDLINE spanning 1980-December 2014. It discusses a number of therapeutic options, paying par-
ticular attention to the mechanisms of action and the clinical evidence for the use of renin-angiotensin system blockade, 
fenofibrate and calcium dobesilate monohydrate in DR. 
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INTRODUCTION 
Diabetes mellitus is a worldwide public health burden 
with the number of people affected by diabetes (mainly type 
2) rising dramatically and estimated to exceed half a billion 
by 2035 (592 million) [1,2]. Over a third of these patients are 
likely to have the microvascular complication of diabetic 
retinopathy (DR) and 10% have vision-threatening stages 
such as diabetic macular edema (DME) or proliferative DR 
(PDR) [3,4]. In fact, despite progress in screening and treat-
ment, DR continues to be leading cause of visual impairment 
and preventable blindness among working-age adults in 
many countries [4,5], and is a significant socioeconomic 
burden on healthcare systems [6-8]. This underlines the im 
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portance of seeking new approaches which go beyond cur-
rent standards of diabetes care. 
The number of patients affected by DR is growing 
worldwide mainly due to the longevity of patients with dia-
betes [9]. As DR remains asymptomatic in the early stages, 
such as mild or moderate non-proliferative DR (NPDR), its 
diagnosis can be deferred. The situation is worse in type 2 
diabetes as patients are often not promptly diagnosed be-
cause diabetes itself may be asymptomatic for many years 
prior to diagnosis. Consequently, this eye complication may 
silently progress at different rates to more severe stages [10]. 
Over the past few decades, epidemiological studies and 
clinical trials show the most important risk factors for the 
development and progression of DR are the type and dura-
tion of diabetes, hyperglycemia and hypertension [4]. Others 
have also identified microalbuminuria and dyslipidemia as 
important risk factors for the progression of DR [11,12]. 
Based on these data, tight control of blood glucose and hy-
pertension are strongly recommended for preventing DR. 
However these therapeutic objectives are usually not easy to 
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achieve in practice and, consequently, DR continues to de-
velop and progress in a high proportion of patients. Addi-
tionally, clinical studies have shown substantial variations 
regarding the onset and severity of DR that are not totally 
explained by these currently known risk factors [13-16]. 
Even multifactorial interventions targeting similar aims to 
those recommended in the American Diabetes Association 
guidelines do not prevent DR in all patients [17]. Finally, 
when DR appears, there is limited treatment that targets the 
eye during the early stages, with most treatments only indi-
cated in the more advanced stages of DR (PDR and clinically 
significant macular edema [CSME]). These include invasive 
and expensive treatments such as laser photocoagulation, 
intravitreal injections of anti-vascular endothelial growth 
factor (VEGF) agents, corticosteroids and vitreoretinal sur-
gery. For all these reasons, there is general agreement that 
new pharmacological treatments for the early stages of DR 
(mild, moderate) are urgently needed [18,19]. 
Several drugs have been developed for the prevention 
and treatment of DR. The protein kinase C inhibitor, ruboxis-
taurin mesilate, administered orally was effective in halting 
DME and vision loss but not in preventing the progression of 
DR (the primary endpoint) [20-22]. In a phase 3 clinical trial 
the long-acting somatostatin analogue, octreotide, given in-
tramuscularly every 4 weeks in moderate-to-severe NPDR to 
low-risk PDR, was not effective in arresting DR progression 
[23]. Consequently, the initial enthusiasm of the scientific 
community for these drugs has dwindled. 
More recently, 2 classes of drugs: renin-angiotensin sys-
tem (RAS) blockers [24,25] and fenofibrate (a hypolipidemic 
drug) [26,27] have emerged as potential systemic treatments 
for DR. Furthermore, calcium dobesilate monohydrate (CaD) 
appears to be a promising treatment for DR, though it is not 
widely used in clinical practice [28]. In this review, the 
mechanisms of action and clinical evidence for the potential 
usefulness of RAS blockers, fenofibrate and CaD in prevent-
ing or delaying DR progression are critically assessed. 
SEARCH STRATEGY AND SELECTION CRITERIA 
References for this review were obtained through a com-
prehensive search of the electronic MEDLINE database 
(1980-2014) using the PubMed search service. Search terms 
included: “diabetic retinopathy”, “diabetic microangiopa-
thy”, and “clinical trials”, and specifically for “candesartan”, 
“fenofibrate”, “renin-angiotensin system blockers”, and “cal-
cium dobesilate”. The search was conducted in April-
December 2014 and all abstracts were reviewed and relevant 
articles retrieved. In addition, reference lists from the se-
lected articles were used to obtain further articles not in-
cluded in the electronic database. Only articles published in 
English were included. 
PATHOPHYSIOLOGICAL MECHANISMS IN  
DIABETIC RETINOPATHY 
The metabolic pathways triggered by chronic hypergly-
cemia (the polyol and the hexosamine pathways, the synthe-
sis de novo of diacylglycerol-proteinkinase C, oxidative 
stress and advanced glycation end-products [AGEs]) are 
instrumental in the onset and progression of DR [29,30]. 
Moreover, growing evidence suggests that chronic inflam-
mation plays an important pathogenic role [31,32]. The acti-
vation of all these pathways results in damage to the neural 
retina (retinal neurodegeneration) and in the capillary bed 
located in the inner retina (microangiopathic injury). Al-
though microcirculatory impairment is the classic hallmark 
of DR, recent evidence suggests that retinal neurodegenera-
tion is an early event in the pathogenesis of DR [33,34]. The 
characteristics features of neurodegeneration are neuronal 
apoptosis and glial dysfunction, whereas early microvascular 
abnormalities are characterized by blood-retinal barrier 
(BRB) breakdown, altered microvascular hemodynamic re-
sponse (impaired neurovascular coupling) and vasoregres-
sion (loss of pericytes and endothelial damage) [34-38] See 
Figs. (1 and 2). 
The multifaceted metabolic and functional alterations 
implicated in the development of DR suggest that those 
treatments targeting multiple pathophysiological mecha-
nisms may be more effective in preventing disease progres-
sion than those blocking only one pathogenic pathway. 
SYSTEMIC TREATMENT FOR DIABETIC RETI-
NOPATHY 
As mentioned earlier, tight control of glycemia and blood 
pressure are established and essential treatments in prevent-
ing and arresting the progression of DR. These strategies are 
not discussed here. 
Recent clinical trials have highlighted RAS blockade and 
fenofibrate as promising systemic treatments for DR [24-27]. 
These treatments should be added to CaD, an angioprotective 
drug approved for DR, although its mode of action is still 
under investigation and clinical outcomes associated with its 
use require further clarification. 
RENIN-ANGIOTENSIN SYSTEM BLOCKADE 
Observational and clinical trials have revealed that blood 
pressure is an important modifiable risk factor for DR and 
that the treatment of hypertension significantly reduces the 
development and progression of DR in both type 1 and type 
2 diabetic patients [39, 40]. The blockade of the RAS with an 
angiotensin converting enzyme (ACE) inhibitor or an angio-
tensin II type 1-receptor (AT1-R) blocker, is one of the most 
common strategies for the management of hypertension in 
diabetic patients. 
The major components of the RAS have been identified 
not only in the kidney but also in ocular tissues and they are 
overexpressed in the diabetic retina [41]. In addition, grow-
ing evidence shows that RAS activation in the eye plays a 
key role in the pathogenesis of DR [41]. For this reason, 
theoretically, along with lowering blood pressure, the block-
ade of the RAS could have an extra value per se in reducing 
the development and progression of DR. 
Mechanisms of Action 
The mechanisms by which RAS activation participates in 
the pathogenesis of DR are summarized in Fig. (3) [41-49]. 
Angiotensin II (AT) binds and activates two primary recep-
tors, AT1-R and AT2-R. In adult humans, activation of the 
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Fig. (1). Pathogenic molecular pathways involved in the pathogenesis of diabetic retinopathy. Abbreviations: AGE, Advanced glycation end-
product; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; NAD+, Nicotinamide adenine dinucleotide (oxidised); NADH, Nicotinamide 
adenine dinucleotide (reduced); NADPH, Nicotinamide-adenine dinucleotide phosphate (reduced); O2, Oxygen; PARP, Poly ADP ribose 
polymerase; PKC, Protein kinase C; ROS, Reative oxygen species. 
 
 
Fig. (2). Pathogenic mechanisms involved in the development of diabetic retinopathy. 
 
AT1-R expressed in endothelial cells and pericytes domi-
nates the pathologic states [41]. AT1-R activation by AT 
produced by the retina stimulates several pathways involved 
in the pathogenesis of DR such as inflammation, oxidative 
stress, AGEs accumulation, neurodegeneration, leukostasis, 
and several crucial mediators of angiogenesis such as VEGF 
and platelet-derived growth factor [41-44]. Most of these 
pathogenic actions are inhibited or attenuated by pharmacol-
ogical blockade of the RAS either at the levels of ACE or the 
AT receptors and are associated with the downregulation of 
VEGF and VEGF receptor-2 [41]. Kim et al. [45] showed 
that perindopril (an ACE inhibitor) attenuated VEGF-
mediated BRB breakdown in rats with streptozotocin-
induced diabetes mellitus (STZ-DM). It is also noteworthy 
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Fig. (3). Renin-Angiotensin-System activation in the pathogenesis of diabetic retinopathy. RAS activation leads to AT-Rs activation (mainly 
AT1-R) which trigger essential pathways involved in the pathogenesis of DR such as inflammation, oxidative stress, neurodegeneration, 
AGEs formation, leucostasis (which is crucial for the release of proinflammatory cytokines and the breakdown of the BRB) and angiogenesis. 
Abbreviations : AGE, Advanced glycation end-product; Angiotensin II, Angiotensin type II; AT1-R, Angiotensin II type 1 receptor; AT2-R, 
Angiotensin II type 2 receptor; BRB, Blood-retinal barrier; BM, Basement membrane; RAS, Renin-Angiotensin System; VEGF, Vascular 
endothelial growth factor. 
 
that candesartan (an AT-R blocker) inhibited retinal accumu-
lation of the AGE product pentosidine in spontaneously dia-
betic Torii rats [46]. Besides reducing microvascular disease, 
recent research points to neuroprotection as a relevant 
mechanism involved in the beneficial effects of AT-R block-
ers in DR [47-49]. 
Clinical Evidence 
The studies in type 2 diabetic patients with hypertension 
suggest that ACE inhibitors and AT-R blockers are not supe-
rior as regards preventing or arresting DR compared to other 
drugs which are as effective in reducing blood pressure such 
as the β-blocker atenolol [50] or the calcium channel blocker 
nisoldipine [51]. These prospective randomized studies sug-
gest that lowering blood pressure is of far greater signifi-
cance than the local effect of RAS blockade in the diabetic 
eye. However, there has been considerable debate concern-
ing the potential beneficial effect of RAS blockers in nor-
motensive diabetic patients. 
In the EURODIAB Controlled Trial of Lisinopril in Insu-
lin-Dependent Diabetes Mellitus (EUCLID) report, lisinopril 
(an ACE inhibitor) did not reduce the incidence of DR in 
normotensive patients (blood pressure ≤ 140/90 mmHg), 
whether they were normoalbuminuric (85% of patients) or 
microalbuminuric. However, lisinopril decreased DR pro-
gression by 2 or more grades and decreased progression to 
PDR [52]. These results have been criticized because the 
placebo group had significantly higher levels of mean 
HbA1c than the treatment group. Indeed, after adjusting for 
baseline HbA1c, only the progression by one level of DR 
remained significant. Study limitations included the short 
follow-up period of 2 years and that DR was not the primary 
endpoint. Consequently, while the EUCLID study suggested 
a potential additional benefit of ACE inhibitors per se on DR 
progression, the study was underpowered for the eye-related 
outcomes. In addition, in normotensive type 2 diabetic pa-
tients in the Appropriate Blood Pressure Control in Diabetes 
(ABC) study, Schrier et al. [53] demonstrated that intensive 
blood pressure control with enalapril (an ACE inhibitor) or 
nisoldipine as the initial antihypertensive agent resulted in 
the same decrease in the progression of DR. Therefore, the 
choice of antihypertensive agent appears to be less signifi-
cant than the attaining of the lower blood pressure targets. 
A more robust research program into this was the Dia-
betic Retinopathy Candesartan Trials (DIRECT) which con-
sisted of two studies conducted in type 1 diabetic patients 
[24] (a primary prevention study, the DIRECT-Prevent 1; 
and a secondary prevention study, the DIRECT-Protect 1) as 
well as a prevention study conducted in type 2 diabetes: DI-
RECT-Protect 2 [25]. In the DIRECT-Prevent 1 study, 1241 
normoalbuminuric and normotensive (blood pressure ≤ 
130/85 mmHg) type 1 diabetic patients without DR were 
randomly assigned to receive candesartan or placebo, with 
median follow-up of 4·7 years [24]. This study showed a 
non-significant reduction (18% relative risk reduction 
[RRR], P = 0·051) in the incidence of DR. However, in a 
post hoc analysis in which the primary endpoint was changed 
from a 2-step increase to at least a 3-step increase in the 
Early Treatment Diabetic Retinopathy Study (ETDRS) scale, 
a significant difference was detected (35% RRR, P = 0·003). 
This beneficial effect was attenuated but still significant after 
the data were adjusted for the duration of diabetes, HbA1c, 
and systolic blood pressure (26% RRR, P = 0·046). The DI-
RECT-Protect 1 study in which 1905 type 1 diabetic patients 
with mild or moderate DR were included, showed that can-
desartan was not effective in preventing DR progression 
[24]. Similarly, candesartan failed to reduce the progression 
of DR in DIRECT-Protect 2, in which 1905 type 2 diabetic 
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program failed to demonstrate any beneficial effect of cande-
sartan, taking into account the primary endpoints. Addition-
ally, the Action in Diabetes and Vascular Disease (AD-
VANCE) study [54], which included 11,140 type 2 diabetic 
patients randomly assigned to intensive glucose control using 
gliclazide (modified release), along with other drugs neces-
sary for achieving HbA1c ≤ 6.5% and an ACE inhibitor-
diuretic combination (perindopril-indapamide), presented the 
same four-year incidence or progression of DR as the pla-
cebo group. These results do not support the hypothesis that 
RAS blockers have an additional benefit with respect to DR 
protection in comparison with other antihypertensive agents. 
In contrast, the classic concept that lowering the blood pres-
sure is the most important strategy regardless of the choice 
of drug has emerged again with renewed rigor. 
FENOFIBRATE 
In recent years, 2 major prospective randomized con-
trolled trials (the FIELD [26,55] and the ACCORD-Eye [27] 
studies) have shown that DR progression in type 2 diabetes 
is significantly reduced by fenofibrate, a peroxisome prolif-
erator activated-receptor alpha (PPARα) used as a hypolipi-
demic agent. 
Mechanisms of Action 
The mechanisms by which fenofibrate exerts its benefi-
cial effects in DR remain to be fully elucidated. The main 
action of fenofibrate is to lower plasma triglyceride, but it 
also reduces total and low-density lipoprotein (LDL) choles-
terol, raises apolipoprotein A1 (apoA1) and high-density 
lipoprotein cholesterol (HDL), and reduces the concentration 
of small dense LDL particles and apolipoprotein B. In the 
FIELD and ACCORD-Eye studies there was no relationship 
between the quantitative changes of serum lipids (total cho-
lesterol, HDL, LDL and triglyceride) and the effects on DR. 
However, it is unknown whether the effectiveness of fenofi-
brate in modulating the qualitative properties of lipoproteins 
(i.e. reducing remnants and small LDL particles) or in lower-
ing lipoprotein-associated phospholipase A2 can contribute 
to its beneficial effects [56,57]. Moreover, the potential ef-
fect of fenofibrate in regulating intraretinal lipid transport 
might be more important than its systemic action [58]. Fi-
nally, it has recently been shown that circulating apoA1 may 
be an independent protective factor for the development of 
DR [59]. Therefore, it is possible that the increase in apoA1 
plasma levels induced by fenofibrate could be added to the 
lipidic-mediated mechanisms involved in its beneficial ac-
tion on DR. 
The hypolipidemic actions of fenofibrate seem more im-
portant in accounting for its effect in reducing the progres-
sion of DR than the lipidic-mediated mechanisms. These 
mechanisms have been recently reviewed [57,60] and are 
summarized in Fig. (4) [61-66]. 
Clinical Evidence 
The FIELD study [55] was a placebo-controlled trial 
primarily designed to assess the effects of fenofibrate on 
major cardiovascular outcomes. In total, 9795 patients were 
included, of whom 4895 were treated with fenofibrate. Af-
ter 5 years, fenofibrate had not significantly reduced the 
primary study outcome, a composite of coronary heart dis-
ease death and myocardial infarction (11% RRR vs. pla-
cebo, P = 0·16). However, the overall incidence of cardio-
vascular events was significantly reduced (11% RRR, P = 
0·035). One of the prespecified tertiary endpoints of the 
study was the necessity of laser photocoagulation. Among 
the 814 patients (8%) with DR at baseline, 3.6% of the pa-
tients treated with fenofibrate versus 5.2% in the placebo 
group required laser therapy over 5 years (P = 0·0003). 
There was greater absolute benefit in patients with, rather 
than without, pre-existing DR [26]. Nevertheless, two ca-
veats exist. First, retinal photographs were only obtained 
from a 10% subsample. Since the initial status of the retina 
is the main determinant of the need for laser therapy during 
follow-up, knowing the status of the retina at study entry is 
of crucial importance. Second, the criteria followed by the 
participating centers for undertaking laser treatment were 
not defined at study entry and, consequently, were likely to 
have been heterogeneous [58]. 
Fig. (4). Effects of fenofibrate in diabetic retinopathy. This figure 
summarizes the reported effects of FA (the active metabolite of 
fenofibrate) on several retinal components such as RPE, BM, 
neuroretina and endothelial cells. In RPE (outer blood retinal 
barrier), FA prevents the disorganisation of tight junctions 
proteins and the hyperpermeability. In addition, FA elicits a dual 
protective effects by down-regulation of stress-mediated 
signalling and induction of autophagy and survival pathways. In 
BM, FA downregulates the overexpression of fibronectin and 
collagen IV, thus further reducing the increase in permeability. In 
the neuroretina FA exerts antioxidant, antinflammatory and 
antiangiogenic actions. Finally, in the endothelial cells, FA 
induces an antiapoptotic action and stimulates NO synthase 
phosphorylation and NO production. Abbreviations: BM, 
basement membrane; FA, Fenofibric acid; RPE, retinal pigment 
epithelium; NO, nitric oxide. 
 
The FIELD study also included an ophthalmology sub-
study in which standardized fundus photographs were rou-
tinely taken at baseline, 2 years and 5 years, and graded with 
ETDRS criteria [26]. A total of 1012 patients without evi-
dence of clinically significant retinopathy (PDR or severe 
NPDR), DME, or a history of laser treatment at baseline 
were included. As in the main trial, there was a significant 
reduction in laser treatment for DR with fenofibrate versus 
placebo (from 4·6%-1·0%, P = 0·0004). However, only 28 
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patients required laser treatment (23 in the placebo and 5 in 
the fenofibrate group). A significant reduction in DR pro-
gression (3 or more steps on the ETDRS) was observed in 
those patients with DR at baseline but not in those without 
DR at baseline (14·6% -3·1%, P = 0·004). 
The ACCORD trial was also primarily a cardiovascular 
outcome study, evaluating whether the intensification and 
extension of current treatment approaches beyond those al-
ready recommended by current guidelines (i.e. intensive vs. 
standard control of blood glucose or blood pressure, or add-
ing fenofibrate against a background of simvastatin treat-
ment) could be beneficial. A combined treatment with fen-
ofibrate plus simvastatin did not have a significant effect on 
cardiovascular outcomes in ACCORD Lipid [67]. Diabetic 
retinopathy outcomes were evaluated in the 4-year AC-
CORD-Eye sub-study [27]. In contrast to FIELD, the pa-
tients in this study had a longer duration of diabetes (mean 
10·0 years vs. median 5·1 years) and a higher prevalence of 
pre-existing DR (50% vs. 8%) at baseline. However, the 
overall results of the ACCORD-Eye study were consistent 
with those observed in the FIELD study. Treatment with 
fenofibrate (n = 806) was associated with a 40% decrease in 
the progression of DR, defined as 3 or more steps on the 
ETDRS scale or PDR that required either laser or vitrectomy 
treatment (10·2% - 6·5%, P = 0·006). There was no effect on 
the rate of moderate vision loss. Once again, the benefit was 
greater in patients with evidence of retinopathy at baseline 
(absolute risk reductions 6·9% vs. 0·2% in those without DR 
at baseline). 
In summary, 2 major clinical trials demonstrated a con-
sistent effect for fenofibrate on DR progression, with a rela-
tive reduction of 30% to 40% over four to five years. In both 
studies, patients with pre-existing DR derived greater bene-
fit. The number needed to treat (NNT) to prevent first laser 
treatment in the main FIELD study was 17; to prevent DR 
progression in the FIELD ophthalmology sub-study the NNT 
was 9, and 14 in ACCORD Eye. Taking these data into con-
sideration it seems reasonable to suggest the use of fenofi-
brate to prevent DR progression in patients with preexisting 
disease. However, to-date, fenofibrate for DR treatment has 
been approved only in Australia. 
CALCIUM DOBESILATE 
Calcium dobesilate monohydrate is indicated and ap-
proved for the treatment of DR in several countries, with 2 
randomized placebo-controlled trials demonstrating its effi-
cacy on the progression of early DR [68,69]. However, it has 
not been widely used in clinical practice and further research 
is still needed to elucidate its pleiotropic mechanism of ac-
tion. 
Mechanisms of Action 
Calcium dobesilate monohydrate has shown multifaceted 
pharmacological effects believed to interfere with the main 
pathophysiological pathways of DR [70], and it has been 
reported that long-term treatment delayed the progression of 
DR in STZ-DM rats [71]. The main effects of CaD in the 
metabolic pathways involved in the pathogenesis of DR are 
shown in Fig. (5). 
The antioxidant and anti-inflammatory properties of CaD 
have been extensively investigated [72-76]. Among these 
mechanisms the inhibition of Nuclear Factor KB (NF-KB)- 
and p38 Mitogen-activated protein kinases (p38 MAPK)-
mediated leukocyte adhesion to retinal vessels, the reduction 
of expression of adhesion molecules such as Intercellular 
Adhesion Molecule 1 (ICAM-1) [77], and reductions in C-
reactive protein in patients with DR should be discussed 
[75]. 
The protective effects of CaD on the inner BRB disrup-
tion have been reported by Rota et al. [78] who observed that 
CaD can prevent albumin leakage from the retinal vessel of 
STZ-DM rats and that this effect was associated with a re-
duced retinal VEGF expression in treated animals compared 
to control. More recently, Leal et al. [77] have shown in 
STZ-DM rats that CaD prevented BRB breakdown by restor-
ing tight junction protein levels and organization, as well as 
decreasing leukocyte adhesion to retinal vessels. These pro-
tective effects of CaD were associated with a decrease of p38 
MAPK and NF-KB activation, perhaps by inhibiting oxida-
tive/nitrosative stress. There is no evidence yet on the poten-
tial effects of CaD in the retinal pigment epithelium, which 
constitutes the outer BRB. 
Fig. (5). Multifaceted effects of calcium dobesilate in essential pathways involved in the pathogenesis of diabetic retinopathy. Abbreviation: 
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The improvement of endothelial-dependent vasodilata-
tion (nitric oxide-dependent) is another mechanism of action 
of CaD [79,80] Calcium dobesilate was also shown to inhibit 
endothelin-1 in patients with DR [81], which can play a role 
in ameliorating vasodilatation impairment. A promising field 
of research would be to assess whether the inhibitory action 
of CaD on endothelin also occurs locally in the retina. This 
could be important for explaining not only the improvement 
in microvascular hemodynamic, but also the amelioration of 
retinal neurodegeneration associated with diabetes. In this 
regard, it should be noted that endothelin has recently been 
shown to be involved in diabetes-induced neuroretinal de-
generation and, therefore, its inhibition seems a promising 
therapeutic target in DR [82-84]. 
The antiangiogenic effect of CaD is supported by studies 
showing its capacity in inhibiting several growth factors such 
as VEGF and fibroblast growth factor [85,86]. In addition, 
CaD abrogates choroidal angiogenesis both in vitro and ex 
vivo in a dose-dependent manner [87]. Furthermore, Demir-
tas et al. [88] have shown in a chick chorioallantoic mem-
brane model that CaD has a potent antiangiogenic effect with 
a dose-dependent action. 
Finally, the beneficial hemorrheologic effects are based 
on the evidence of CaD in reducing blood hyperviscosity and 
platelet aggregation, as well as decreasing red blood cell 
hyperaggregation and increasing fibrinolysis [89-96]. These 
are established pharmacological effects that account for cap-
illary perfusion amelioration and inflammatory status reduc-
tion [96]. CaD has also been shown to reduce the prothrom-
botic state through reduced platelet aggregation and the syn-
thesis of platelet activating factor [97]. 
In summary, CaD abrogates multiple pathogenic path-
ways involved in DR. This should be contemplated as a sig-
nificant advantage in treating a disease in which multiple 
pathways are simultaneously activated by hyperglycemia. 
However, further research is recommended to better under-
stand the mechanisms by which CaD has beneficial effects in 
DR. 
Clinical Evidence 
The present evidence supports the beneficial role of CaD 
in the early stages of the disease, in stabilizing the BRB and 
preventing or delaying the progression to more advanced 
stages (severe NPDR and PDR), thus potentially reducing 
the need for laser photocoagulation [28]. The effect of CaD 
on the progression of early DR is shown in two randomized 
placebo-controlled studies [68, 69]. 
In the study by Leite et al. [68] the effect of CaD on the 
alteration of the BRB was studied in 41 adult-onset, type 2 
diabetic patients with minimal or no retinopathy. Patients 
were randomly assigned to receive either oral 2 g CaD (two 
500 mg capsules, twice daily) or a placebo, for 12 months. 
The integrity of the BRB was assessed by vitreous fluoro-
photometry (posterior vitreous penetration ratio [PVPR]), 
with CaD shown to prevent leakage due to the breakdown of 
the BRB. In addition, no adverse events were reported as 
related to CaD. 
In the Ribero et al. study [69] vitreous fluorophotometry 
(primary endpoint PVPR) was also used to assess BRB per-
meability in type 2 diabetic patients with early stages of DR. 
The sample size was higher (194 at study entry, 137 at com-
pletion) and the follow-up was longer (2 years) than the 
study by Leite et al. [68] The authors concluded that CaD (2 
g daily for two years) showed a significantly better activity 
than placebo in preventing BRB disruption, independent of 
diabetes control. A further analysis of the secondary parame-
ters revealed significant changes from baseline to the last 
visit in favor of CaD, with respect to hemorrhages (P = 
0·029), DR level (P= 0·0006) and microaneurysms (P = 
0·013). Finally, this study showed that CaD has a good bene-
fit-risk profile. 
A randomized, double-blind, placebo-controlled, multi-
centre study (40 centers in 11 countries; the CALDIRET 
study) conducted in 635 type 2 diabetic patients with mild-
to-moderate NPDR presenting at the first visit with microal-
buminuria and with a follow-up period of five years, showed 
that CaD did not reduce the risk of the development of 
CSME [98]. The drop-out rate was high with only 150 pa-
tients completing the 5-year follow-up. More men were as-
signed to the CaD group than to the placebo group. Explora-
tory post-hoc analysis to ascertain the effect of gender bias 
showed positive results in the CaD group for a subgroup of 
women with HbA1c ≥ 9%; this was even more evident when 
poorly controlled hypertension was linked. No relevant ad-
verse drug reactions were noted. The main differences in the 
characteristics of the patients included in this study in com-
parison with the 2 previously mentioned were the inclusion 
of patients with more advanced stages of DR and microal-
buminuria as per inclusion criteria. In addition, a lower dose 
of CaD was used (1·5 g/day). 
Finally, a recent systematic review and meta-analysis 
have shown that CaD was significantly associated with im-
proving retinal microaneurysms, hemorrhages, exudates, as 
well as reduction of whole blood and plasma viscosity [99]. 
Overall the current evidence suggests that CaD is benefi-
cial in the very early stages of DR but its effectiveness in 
more advanced stages remains to be proven. 
SUMMARY OF CURRENT EVIDENCE AND NEW 
PERSPECTIVES 
The paucity of relevant clinical studies investigating and 
testing new drugs in DR is due partly to the need for long-
term studies to be conducted in large cohorts of patients with 
diabetes, which requires standardized masked grading of 
retinal photographs. The duration of the trial should be con-
sistent with the natural history of DR and, consequently, at 
least five years seems to be necessary for separating the 
mechanisms of DR in the intervention and control groups. In 
addition, most clinical trials have had the aim of evaluating 
the progression of DR, whereas there have been few studies 
targeting prevention. 
The current clinical evidence does not support the con-
cept that RAS blockers have an extra value in preventing or 
arresting the progression of DR in hypertensive diabetic pa-
tients when compared with other anti-hypertensive agents. In 
addition, in normotensive type 2 diabetic patients candesar-
tan failed to reduce either the incidence of DR or its progres-
sion. Fenofibrate has been useful in arresting the progression 
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of DR but not in preventing its development. Finally, CaD 
seems effective in the very early stages of DR but not in 
more advanced stages. Further studies are needed to confirm 
this scenario and both diabetologists and ophthalmologists 
should work together not only in future research, but also in 
establishing international clinical guidelines in which the 
role of these drugs can be incorporated. 
Optical coherence tomography (OCT), used for monitor-
ing the development of DME, could be very useful to assess 
the effect of medical treatments in the early stages of DR. In 
addition, flicker-induced vasodilatation coupled to multifocal 
electroretinography/Fourier Domain-OCT could help in ex-
amining their potential beneficial actions on the neurovascu-
lar unit. These methods could permit us to examine the early 
effect of these drugs in DR, thus reducing the follow-up pe-
riod and, consequently, the associated economic burden. 
Finally, topical administration with eye-drops could pro-
vide a new approach in the treatment of DR. This could be 
an effective route for DR treatment with the advantage of 
overcoming the BRB and minimizing potential systemic 
adverse effects. The ongoing clinical trial EUROCONDOR 
(http://eurocondor.eu) should provide the scientific commu-
nity with some information regarding the potential effective-
ness of eye-drops containing neuroprotective agents, in the 
early stages of DR. 
In summary, systemic treatment with drugs that specifi-
cally address the reduction in incidence and progression of 
DR, added to current standards of tight glycemic and blood 
pressure control could be very useful in improving public 
health and clinical outcomes and reducing the burden of DR. 
In addition, clinical trials aimed at exploring the eventual 
beneficial effect of these drugs in enhancing the effective-
ness of treatments used in advanced stages of DR (i.e. laser 
photocoagulation, intravitreal injection of anti-VEGF agents) 
are required. Finally, further efforts in understanding the 
mechanisms of action, as well as in answering key clinical 
questions (who to give to, when to start, how long to treat) 
are urgently needed. 
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